Drug Trial Radar · NCT04797650
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Jun 10, 2021
Primary completion
Jun 8, 2022
Study completion Jun 29, 2022
Sponsor
- Lead sponsor
- Concert PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
Conditions
- Alopecia Areata
Interventions
CTP-543 matching placeboDrug
Administered as tablets.
CTP-543Drug
Administered as tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24Time frame: Week 24
Locations
63 sites in 7 countries. Site status is shown where the registry gives one.
Alliance Dermatology & Mohs Center
Phoenix, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Dermatology Research Associates
Los Angeles, California
University of Miami Hospital
Miami, Florida
Floridian Research Institute LLC
Miami, Florida
MetroBoston Clinical Partners, LLC
Brighton, Massachusetts
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Galen Research
Chesterfield, Missouri
Vivida Dermatology
Las Vegas, Nevada
The Dermatology Group P.C.
Verona, New Jersey
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center - Department of Dermatology
New York, New York
University of Rochester
Rochester, New York
Dermatologists of Southwest Ohio
Mason, Ohio
Oregon Medical Research
Portland, Oregon
Velocity Clinical Research - Providence
Warwick, Rhode Island
The Skin Wellness Center
Knoxville, Tennessee
North Texas Center for Clinical Research
Frisco, Texas
Elixir Research Group
Houston, Texas
Progressive Clinical Research
San Antonio, Texas
Velocity Clinical Research/Gateway
Salt Lake City, Utah
Velocity Clinical Research/Swinyer-Woseth Dermatology
Salt Lake City, Utah
Jordan Valley Dermatology Center
South Jordan, Utah
The Rector and Visitors of the University of Virginia
Charlottesville, Virginia
Centre de Recherche Saint-Louis
Québec, Canada
Centre de Recherche Dermatologique du Quebec Metropolitan
Québec, Canada
Care Clinic Ltd.
Red Deer, Alberta, Canada
Medical Arts Health Research Group
Kelowna, British Columbia, Canada
Kingsway Clinical Research
Etobicoke, Ontario, Canada
North Bay Dermatology Centre
North Bay, Ontario, Canada
The Centre for Dermatology
Richmond Hill, Ontario, Canada
Centre Hospitalier Universitaire de Nice - Hôpital Archet 2
Nice, Alpes-maritimes, France
Chru de Brest - Hôpital Morvan
Brest, Finestère, France
Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Erlangen Hautklinik
Erlangen, Germany
Universitaetsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Klinikum Rechts Der Isar, Technische Universität München
Munich, Bavaria, Germany
Universitätsklinikum Frankfurt Klinik Für Dermatologie, Venerologie Und Allergologie
Frankfurt am Main, Hesse, Germany
Fachklinik Bad Bentheim - Dermatologische Studienambulanz
Bad Bentheim, Lower Saxony, Germany
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.